Co-op Student, Bioconjugation

Zymeworks Inc.

2mo ago

Applications are closed

Internship
Full-time
Off-cycle Internship
Research & Development
Science
Vancouver

Requirements

Currently enrolled in an undergraduate program in Biology, Biochemistry, Chemistry, Immunology or a related discipline and successful completion of at least one relevant co-op term are required. Availability for an 8 month co-op term is also required.
Skills and Abilities:
Proven interpersonal skills with the ability to work collaboratively as a member of cross-functional team. Ability to establish and maintain effective working relationships
Good organizational skills and the ability to work effectively in a high paced, fast changing environment. Results-oriented
Experience working with antibodies or bioconjugation would be an asset
Experience with automated systems and liquid handlers would be an asset
Experience involving mammalian tissue culture, FACS, SDS-PAGE, protein purification and quantification, ELISA, or HPLC would be an asset
Excellent oral and written communication capabilities
Good computer skills particularly with Excel and PowerPoint
Basic working knowledge of antibody structure and function

Responsibilities

Performs bioconjugation experiments to attach small molecules to antibodies and other proteins
Characterizes antibodies and antibody-drug conjugates using HPLC-HIC, HPLC-SEC, SDS-PAGE, CE-SDS, flow cytometry and other methods as required
Assists with functional characterization of bioconjugates using, for example, cell growth inhibition assays
Performs experiments, interprets and analyzes data, and prepares presentations for group meetings
Conducts all activities in accordance with scientific standards, OS&H regulations and established Zymeworks’ policies and practices
Adheres to Zymeworks standard procedures for generating, documenting and archiving data, maintaining an accurate, up-to-date lab notebook or electronic notebook
Contributes to a safe and highly efficient laboratory environment through ordering of consumables, preparation of solutions, stocking of consumables, and maintaining a clean working environment

Zymeworks Inc.

Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases.

Science & Healthcare

Industry

201-500

Employees

2003

Founded Year

Mission & Purpose

Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second product candidate, Zanidatamab Zovodotin (ZW49), is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.